Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis.

ABSTRACT:

Background

Polyethylene glycol (PEG) may elicit anaphylaxis to COVID-19 mRNA vaccines, and guidance for patients at risk is needed.

Methods

In retrospective patients with PEG allergy collected from 2006 till 2019, clinical, skin, and basophil activation test (BAT) characteristics discriminative for PEG allergy were analyzed and compared with the literature. In 421 prospective real-life patients asking for allergy workup for COVID-19 vaccine hypersensitivity in 2020/2021, risk assessment was performed and tolerance of the recommended vaccination approach was assessed.

Results

Ten patients with PEG allergy were found in the retrospective cohort. Patients reacted with immediate anaphylaxis (100%) not only to PEG-based laxatives/bowel preparations or injections, but also

SUBMITTER: Brockow K 

PROVIDER: S-EPMC9011687 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature